Nanobioanálisis
NBA


Hospital Morales Meseguer
Murcia, EspañaPublications in collaboration with researchers from Hospital Morales Meseguer (8)
2024
-
Cardiac events after allo-HCT in patients with acute myeloid leukemia
Blood Advances, Vol. 8, Núm. 21, pp. 5497-5509
-
Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC
Bone Marrow Transplantation, Vol. 59, Núm. 12, pp. 1694-1703
-
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256
-
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial
Haematologica, Vol. 109, Núm. 12, pp. 4056-4066
2023
-
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
Haematologica, Vol. 108, Núm. 10, pp. 2753-2763
2022
-
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852
-
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)
Leukemia and Lymphoma, Vol. 63, Núm. 14, pp. 3438-3447
2019
-
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Blood, Vol. 134, Núm. 16, pp. 1337-1345